TapImmune is a leading innovator and world-class clinical-stage immuno-oncology company. The company is developing next-generation T-cell vaccines with an initial focus on treating women’s cancers, specifically ovarian and breast cancer. Stimulating human T-cells as therapeutics is what TapImmune is all about. We have selected potent antigen combinations that target disease-specific molecules and can be recognized by the vast majority of patients’ immune systems. TapImmune is developing vaccine immunotherapies designed to create a lasting “memory” T-cell response that may be effective against both the primary tumor and metastases.